A Multicenter, Randomized Trial for Stage IIIB or IV NSCLC Comparing Weekly Taxol(Paclitaxel) and Carboplatin(Paraplatin) Regimen Versus Standard Taxol and Carboplatin Administered Every Three Weeks, Followed by Weekly Taxol.

Inclusion Criteria

Inclusion criteria:

- Confirmation of non-small cell bronchogenic carcinoma (epidermoid, squamous, adeno,
large cell anaplastic carcinoma, but no small cell or carcinoid) must be
histologically or cytologically confirmed.

- No prior antineoplastic chemotherapy, hormonal therapy or therapy with biological
response modifiers

- No previous irradiation to the only area of measurable disease.

Exclusion Criteria:

- Past or current history of neoplasm other than the entry diagnosis. Exceptions are
curatively treated basal cell or squamous cell skin cancer, carcinoma in situ of the
cervix or other cancers treated by surgery or radiation with a disease free survival
longer than 5 years.

- Patients who have undergone surgery less than 3 weeks prior to enrollment.

- History of serious cardiac disease not adequately controlled.

- Patients with serious active infections or other serious underlying medical
condition.

- Uncontrolled diabetes mellitis.